A similar trial for Ozempic, a type 2 diabetes drug that uses the same ingredient, semaglutide, showed that it reduced the risk of heart attack, stroke and heart-related death by 26% over two years, compared to placebo.

Dr. Brian Kolski, a cardiologist at Orange County Heart Institute and director of Structural Heart Disease at Providence St. Joseph Hospital in Orange County, CA, said the heart-related benefits of Wegovy are not unexpected.

“[This class of drugs] do seem to be quite effective in producing weight loss,” he told Healthline, “and that weight loss, as we would expect, should have some cardiovascular benefits.”

Other treatments for obesity also show heart-related benefits. For example, the largely plant-based Mediterranean diet lowers the risk of coronary heart disease, stroke, and overall cardiovascular disease. It has also been linked to moderate weight loss over the short term.

Bariatric surgery, another treatment for obesity, has been shown to reduce the risk of cardiovascular disease, with stronger results than the Wegovy trial.

“Multiple studies show bariatric surgery patients experience a significant decrease in the risk of developing major cardiovascular events such as heart attacks, heart failure or ischemic strokes,” Eid told Healthline.

In a five-year study published in 2021, bariatric surgery reduced the risk of heart attack, stroke, or dying from any cause by 44% in people with obesity; it also reduced the risk of dying from cardiovascular disease by 65%. Both were in comparison to people with obesity who didn’t undergo surgery.

According to Nova Nordisk’s release, Wegovy “appeared to have a safe and well-tolerated profile,” in line with previous trials of the drug, but the company didn’t provide details from the new study.

The release also did not discuss the effects of the drug on each specific measure: heart attack, stroke and cardiovascular death.

However, given the promising new results, Wegovy “has the potential to change how obesity is regarded and treated,” Martin Holst Lange, executive vice president for development at Novo Nordisk, said in the release.

Eid agreed and said that once the full trial results are published, it will “potentially result in cardiovascular risk factors being considered as indications for insurance coverage of Wegovy.” As a result, “it could be prescribed to patients with obesity at risk of cardiovascular disease,” he added.

The company said it would ask the Food and Drug Administration (FDA) and European regulators this year to add cardiovascular benefits to the drug’s prescribing information.

Eid also thinks the new trial may shift the discussion of obesity to be firmly considered a medical condition. “This can help with creating better treatments,” he said.

Kolski pointed out that doctors who work with patients with obesity already realize there’s more to weight loss than just eating less and exercising more.

“There’s definitely a component that’s genetic, that’s metabolic,” he said. “So this drug is another tool to help those patients, besides diet and lifestyle modifications.”

Demand for Wegovy is already high, with Novo Nordisk struggling to keep up. Once the new trial results are published in a peer-reviewed journal, even more doctors may prescribe the drug.

Currently, Medicare does not cover Wegovy or other anti-obesity drugs. In addition, some insurance companies and employers recently ended coverage of Wegovy and similar medications due to increasing costs.

However, the publication of the full results from the new trial may improve health insurance coverage of Wegovy, which costs $1,349 a month before insurance.

If more research data becomes available, some insurance companies may become more willing to cover Wegovy for heart disease prevention among people who have obesity, CNBC reported — though a long road still lies ahead.

Right now, though, access to anti-obesity drugs continues to be an issue for many Americans.

Randa Deaton, vice president of purchaser engagement for Purchaser Business Group on Health, a nonprofit coalition representing nearly 40 private employers and public entities, said while positive results from clinical trials are encouraging, the ultimate issue is affordability and its impact on access.

“Employers are committed to covering medications in line with appropriate use,” she told Healthline, “but employers and employees continue to struggle with excessive drug prices and costs.”

“If these drugs are indeed producing such good health outcomes with potential for a tremendous new patient pool,” she added, “why would the pharmaceutical companies not price them more competitively to make access and affordability less of a barrier?”

A new study from Novo Nordisk found the anti-obesity drug Wegovy reduced the risk of heart attack, stroke and heart-related death by 20% in people taking the drug compared to people taking a placebo.